TriangleCalderasib (NCT07209111)
Calderasib trial for Neoplasm Malignant (NCT07209111). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with a KRAS G12C-mutated solid tumor that is unresectable or metastatic and has progressed after standard systemic treatment. Colorectal cancers and primary brain tumors are excluded.
The idea: compare oral calderasib alone with calderasib plus cetuximab infusions every two weeks. Calderasib targets KRAS G12C growth signaling; cetuximab blocks EGFR signaling. Researchers measure tumor response and safety. Treatment has no fixed maximum cycle count but stops when protocol discontinuation criteria apply.
This phase 2 study plans 150 patients. Merck sponsors six recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.